glp-1 ra medications New Guidelines for Type 2 Diabetes in 2025 List of approved and pending

In 2005, exenatide received FDA approval to treat diabetes under the name Byetta

Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with Type 2 diabetes and obesity

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm2016: executive summary

Studies that include patients who are considered at-risk (i.e., diabetics, cardiac, elderly, etc.) and are currently taking GLP-1 RAs should also be performed as these patients may have compounding risk during the perioperative period which may make them more susceptible to complications related to GLP-1 use (Santos et al